M. Shum

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

Ignace Vergote, José Alejandro Pérez Fidalgo, Erika Hamilton et al. · Journal of Clinical Oncology · 2023 · 71 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

David R. Spigel, Robert M. Jotte, John Nemunaitis et al. · Journal of Thoracic Oncology · 2020 · 50 citations · Full text

Medicine, Oncology, Pharmacology +14

A Sheep in Wolf’s Clothing

Chirag J. Dalsania, Vivek Khemka, M. Shum et al. · The American Journal of Medicine · 2008 · 40 citations

Life Sciences, Animal Sciences, Animal Behavior +1

KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRAS^G12C mutation.

Tony Mok, William Lawler, M. Shum et al. · Journal of Clinical Oncology · 2021 · 31 citations

Medicine, Oncology, Pharmacology +17

Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Autoimmune Hemolytic Anemia (AIHA)

F Grossi, M. Shum, Morie A. Gertz et al. · Blood · 2018 · 26 citations

Life Sciences, Hematology, Immunology +14